Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Mirum Pharmaceuticals Inc (NQ: MIRM ) 39.61 -1.88 (-4.53%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 3, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Mirum Pharmaceuticals Inc < Previous 1 2 3 4 Next > MIRM Stock Earnings: Mirum Pharmaceuticals Misses EPS, Beats Revenue for Q2 2024 August 07, 2024 MIRM stock results show that Mirum Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. Via InvestorPlace Nvidia To Rally Around 53%? Here Are 10 Top Analyst Forecasts For Tuesday June 18, 2024 Via Benzinga Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session June 17, 2024 Via Benzinga Analyst Ratings For Mirum Pharmaceuticals May 09, 2024 Via Benzinga Analyst Ratings For Mirum Pharmaceuticals April 17, 2024 Via Benzinga Cracking The Code: Understanding Analyst Reviews For Mirum Pharmaceuticals March 18, 2024 Via Benzinga 12 Health Care Stocks Moving In Monday's Intraday Session June 17, 2024 Via Benzinga Mirum Pharmaceuticals Highlights Encouraging Data For Rare Liver Disease Therapy From Two Mid-Stage Studies June 17, 2024 Mirum Pharmaceuticals announced promising interim results from Phase 2b studies of volixibat for primary biliary cholangitis and primary sclerosing cholangitis. Significant improvements in pruritus and... Via Benzinga Aaron's, Nvidia, Mirum Pharmaceuticals, Primo Water And Other Big Stocks Moving Higher On Monday June 17, 2024 Via Benzinga MIRM Stock Earnings: Mirum Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024 May 08, 2024 MIRM stock results show that Mirum Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. Via InvestorPlace $5M Bet On Snowflake? Check Out These 4 Stocks Insiders Are Buying March 28, 2024 Although U.S. stocks closed higher on Wednesday, there were a few notable insider trades. Via Benzinga Critical Insights From Mirum Pharmaceuticals Analyst Ratings: What You Need To Know February 29, 2024 Via Benzinga Mirum Pharmaceuticals: Q4 Earnings Insights February 28, 2024 Via Benzinga Preview: Mirum Pharmaceuticals's Earnings February 27, 2024 Via Benzinga FDA Approves Mirum's Livmarli For Liver Disease In Kids As Young As 5 Years: Analyst Bullish On Label Expansion Strategy March 14, 2024 FDA approves Livmarli by Mirum Pharmaceuticals for cholestatic pruritus in PFIC patients ≥5 years old. Data from Phase 3 MARCH study. Analysts bullish on broader coverage in 2024, with price target... Via Benzinga Exposures Product Safety Where Mirum Pharmaceuticals Stands With Analysts January 11, 2024 Via Benzinga Veradigm, Aehr Test Systems, Saratoga Investment And Other Big Stocks Moving Lower On Wednesday January 10, 2024 U.S. stocks traded slightly higher, with the Dow Jones index gaining over 20 points on Wednesday. Shares of Veradigm Inc. (NASDAQ: MDRX) shares fell sharply during Wednesday’s session. Via Benzinga Topics Stocks Exposures US Equities The Latest Analyst Ratings For Mirum Pharmaceuticals December 19, 2023 Via Benzinga Uber To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Tuesday December 19, 2023 Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Via Benzinga 11 Analysts Have This to Say About Mirum Pharmaceuticals November 20, 2023 Via Benzinga Analyst Ratings for Mirum Pharmaceuticals November 03, 2023 Via Benzinga Why Lantheus Holdings Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Monday's Mid-Day Session December 18, 2023 Shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) fell sharply during Monday’s session after the company and POINT Biopharma announced topline results from the pivotal phase 3 SPLASH study in metastatic... Via Benzinga Earnings Outlook For Mirum Pharmaceuticals November 01, 2023 Via Benzinga 7 Small-Cap Stocks That Get the Nod from Wall Street October 11, 2023 Although small-cap stocks tend to be extremely risky, these compelling ideas just happen to get the nod from Wall Street analysts. Via InvestorPlace Analyst Ratings for Mirum Pharmaceuticals October 09, 2023 Via Benzinga Analyst Ratings for Mirum Pharmaceuticals September 13, 2023 Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023 October 24, 2023 Via Benzinga Why Shares of Travere Therapeutics Are Slumping Thursday September 21, 2023 A mixed trial could hurt a kidney drug's chances of full approval. Via The Motley Fool Benzinga's Top Ratings Upgrades, Downgrades For September 20, 2023 September 20, 2023 Via Benzinga Around $4M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying September 06, 2023 Although U.S. stocks closed mostly lower on Tuesday, there were a few notable insider trades. Via Benzinga < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.